Skip to content

Clinical and basic study of ulinastatin affecting pulmoary vascular permeability of ARDS complicating sepsis on clinical curative effect and concentration-response relationship

Clinical and basic study of ulinastatin affecting pulmoary vascular permeability of ARDS complicating sepsis on clinical curative effect and concentration-response relationship

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014452
Enrollment
Unknown
Registered
2018-01-15
Start date
2016-02-01
Completion date
Unknown
Last updated
2018-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis, acute respiratory distress syndrome

Interventions

Low dose group:Ulinastatin 400000 units/day
High dose group:Ulinastatin 800000 units/day

Sponsors

The Third Hospital of Hebei Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) aged 18 to 70 years old, men and women; (2) in accordance with the above sepsis ARDS diagnostic criteria; (3) sepsis diagnosed ARDS to include test time 12 hours or less; (4) all needs to accept patients with endotracheal intubation and ventilator help to breathe.

Exclusion criteria

Exclusion criteria: (1) pregnant women, lactation and possible pregnancy women; (2) influence the survival of the patients with severe illness (for example, unresectable tumors, blood disease, cerebrovascular disease, leading to long-term lie in bed, dementia, etc.); (3) acute myocardial infarction (< 1 week); (4) with acute renal failure; (5) AECOPD; (6) from pulmonary fibrosis; (7) clear of valvular heart disease and heart failure; (8) drug allergies; (9) in patients with mental illness; (10) doctors recorgnized not eligible for inclusion.

Design outcomes

Primary

MeasureTime frame
Bedside ultrasound lung lung water index;PICCO blood vessels outside the lung water (EVLWI) and pulmonary permeability index (PVPI);Bronchoalveolar lavage fluid protein content determination;Vascular permeability related factor (ET - 1, TM, vWF);Blood gas analysis (PO2 / FiO2, PO2 (A - A));

Secondary

MeasureTime frame
28 days survival rate;The length of time;Mechanical ventilation time;APACHE II score;SOFA score;

Countries

China

Contacts

Public ContactWang Zhiyong

The Third Hospital of Hebei Medical University

wzyphd@126.com+86 18533112993

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026